María‐Victoria Mateos

Research interests

Publications

• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2303379

• Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

  New England Journal of Medicine · 2022 · 10.1056/nejmoa2204591

• The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

  Blood · 2022 · https://doi.org/10.1182/blood.2022015851

• Teclistamab in Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203478

• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2020.11.014

• Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0876-z

• International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30309-2

• Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

  The Lancet · 2019 · 10.1016/s0140-6736(19)32956-3

• Multiple myeloma

  Nature Reviews Disease Primers · 2017 · 10.1038/nrdp.2017.46

• Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1714678

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx096

• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

  Blood · 2016 · 10.1182/blood-2016-01-631200

• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1606038

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

  The Lancet · 2016 · 10.1016/s0140-6736(15)01120-4

• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1505654

• Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

  Blood · 2015 · 10.1182/blood-2014-12-615187

• Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

  Blood · 2014 · 10.1182/blood-2014-01-550020

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1300439

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

  The Lancet Oncology · 2010 · 10.1016/s1470-2045(10)70187-x

• Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.26.0638

• Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

  Blood · 2008 · 10.1182/blood-2008-05-159624

• International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

  Leukemia · 2008 · 10.1038/leu.2008.307

• New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

  Blood · 2007 · 10.1182/blood-2007-05-088443

Current projects

No projects listed.